154 related articles for article (PubMed ID: 27736268)
21. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
22. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
23. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells.
Rodríguez JA; Luria-Pérez R; López-Valdés HE; Casero D; Daniels TR; Patel S; Avila D; Leuchter R; So S; Ortiz-Sánchez E; Bonavida B; Martínez-Maza O; Charles AC; Pellegrini M; Helguera G; Penichet ML
Leuk Lymphoma; 2011 Nov; 52(11):2169-78. PubMed ID: 21870996
[TBL] [Abstract][Full Text] [Related]
24. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
[TBL] [Abstract][Full Text] [Related]
25. L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.
Rosilio C; Nebout M; Imbert V; Griessinger E; Neffati Z; Benadiba J; Hagenbeek T; Spits H; Reverso J; Ambrosetti D; Michiels JF; Bailly-Maitre B; Endou H; Wempe MF; Peyron JF
Leukemia; 2015 Jun; 29(6):1253-66. PubMed ID: 25482130
[TBL] [Abstract][Full Text] [Related]
26. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
Trinquand A; Tanguy-Schmidt A; Ben Abdelali R; Lambert J; Beldjord K; Lengliné E; De Gunzburg N; Payet-Bornet D; Lhermitte L; Mossafa H; Lhéritier V; Bond J; Huguet F; Buzyn A; Leguay T; Cahn JY; Thomas X; Chalandon Y; Delannoy A; Bonmati C; Maury S; Nadel B; Macintyre E; Ifrah N; Dombret H; Asnafi V
J Clin Oncol; 2013 Dec; 31(34):4333-42. PubMed ID: 24166518
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effects of ginkgetin against neuroinjury in Parkinson's disease model induced by MPTP via chelating iron.
Wang YQ; Wang MY; Fu XR; Peng-Yu ; Gao GF; Fan YM; Duan XL; Zhao BL; Chang YZ; Shi ZH
Free Radic Res; 2015; 49(9):1069-80. PubMed ID: 25968939
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
29. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
[TBL] [Abstract][Full Text] [Related]
30. Effects of iron depletion on CALM-AF10 leukemias.
Heath JL; Weiss JM; Lavau CP; Wechsler DS
Exp Hematol; 2014 Dec; 42(12):1022-1030.e1. PubMed ID: 25193880
[TBL] [Abstract][Full Text] [Related]
31. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
32. High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines.
Bajbouj K; Shafarin J; Hamad M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818764470. PubMed ID: 29562821
[TBL] [Abstract][Full Text] [Related]
33.
Menghini S; Ho PS; Gwisai T; Schuerle S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419059
[TBL] [Abstract][Full Text] [Related]
34. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
35. Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.
Haney SL; Varney ML; Safranek HR; Chhonker YS; G-Dayanandan N; Talmon G; Murry DJ; Wiemer AJ; Wright DL; Holstein SA
Leuk Res; 2019 Feb; 77():17-27. PubMed ID: 30612055
[TBL] [Abstract][Full Text] [Related]
36. Deferoxamine attenuates lipopolysaccharide-induced inflammatory responses and protects against endotoxic shock in mice.
Wang S; Liu C; Pan S; Miao Q; Xue J; Xun J; Zhang Y; Gao Y; Duan X; Fan Y
Biochem Biophys Res Commun; 2015 Sep; 465(2):305-11. PubMed ID: 26277391
[TBL] [Abstract][Full Text] [Related]
37. Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.
Alonso-Alonso R; Mondéjar R; Martínez N; García-Diaz N; Pérez C; Merino D; Rodríguez M; Esteve-Codina A; Fuste B; Gut M; Burrows F; Scholz C; Vaqué JP; Gualberto A; Piris MÁ
Sci Rep; 2020 Apr; 10(1):6721. PubMed ID: 32317694
[TBL] [Abstract][Full Text] [Related]
38. Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line.
Tüfekçi Ö; Yandım MK; Ören H; İrken G; Baran Y
Leuk Res; 2015 Mar; 39(3):342-7. PubMed ID: 25557384
[TBL] [Abstract][Full Text] [Related]
39. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
40. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine.
Gharagozloo M; Khoshdel Z; Amirghofran Z
Eur J Pharmacol; 2008 Jul; 589(1-3):1-7. PubMed ID: 18619590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
